Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head AnalysisDefense World · Oct 10, 2026
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&DSeeking Alpha · Oct 4, 2026
Pyxis Oncology Announces Closing of Up to $282.6 Million Public OfferingGlobeNewsWire · Oct 2, 2026
Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)Defense World · Oct 1, 2026
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public OfferingGlobeNewsWire · Sep 30, 2026
Pyxis Oncology Announces Proposed Public OfferingGlobeNewsWire · Sep 29, 2026Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.35 | -$0.40 | Miss |
| May 14, 2026 | -$0.35 | -$0.37 | Miss |
| Mar 23, 2026 | -$0.35 | -$0.29 | Beat |
| Nov 3, 2025 | -$0.36 | -$0.35 | Beat |
| Aug 14, 2025 | -$0.36 | -$0.30 | Beat |
| May 15, 2025 | -$0.29 | -$0.35 | Miss |